Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Sophie Postel-VinayJuan CovesMatthieu TexierMihaela AldeaAnas GazzahManuel DómineDavid PlanchardRamon De Las PeñasMa Angeles Sala GonzalezSantiago ViteriJavier PerezAna Laura OrtegaTeresa MoranCarlos CampsAna Lopez-MartinMariano ProvencioJean-Charles SoriaBenjamin BesseBartomeu MassutiRafael RosellPublished in: British journal of cancer (2023)
PIPSeN was terminated early after enrollment of only 50% of the pre-planned population, thus being statistically underpowered. Olaparib maintenance did neither improve median PFS nor OS in this patient population.